Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.49 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276927 | 0.84 | PTGS2 (0.53) | PTGS2NR1H4SRCS1PR1 | |
| SCHEMBL22276934 | 0.83 | PTGS2 (0.50) | PTGS2EPHB4P2RY14TEKNR1H4 | |
| SCHEMBL22276803 | 0.82 | SRC (0.54) | NR1H4SRC | |
| SCHEMBL22276762 | 0.81 | SRC (0.72) | PTGS2EPHB4TEKNR1H4SRC | |
| SCHEMBL30556704 | 0.81 | SRC (0.58) | PTGS2SRC | |
| SCHEMBL29050563 | 0.81 | SRC (0.63) | PTGS2EPHB4P2RY14TEKSRC | |
| SCHEMBL22276761 | 0.80 | SRC (0.58) | NR1H4SRC | |
| SCHEMBL22276931 | 0.79 | MEN1 (0.56) | PTGS2SRCHSP90AA1HSP90AB1 | |
| SCHEMBL30531809 | 0.78 | SRC (0.63) | PTGS2EPHB4TEKSRCKDR | |
| SCHEMBL22276773 | 0.78 | HDAC8 (0.57) | NR1H4SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| US-20230266321-A1 | LIVE CELL ENGAGEMENT ASSAY | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-08-24 | — | — | US | disclosed |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230266321-A1 | LIVE CELL ENGAGEMENT ASSAY | KSR1, KSR2, ARAF | PTGS2 4673/4885EPHB4 913/4885P2RY14 3017/4885 |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | NEU1, NEU3, NEU2 | PTGS2 2779/4885EPHB4 1725/4885P2RY14 3119/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | PTGS2 2779/4885EPHB4 1725/4885P2RY14 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.